WT1 and neoplasm: Dao et al. reported the potential efficacy of bispecific antibody directed to WT1-derived peptide in the context of HLA-A2.26 Ahmed et al. reported the TCR-like bispecific antibody targeting EBV LMP2A-derived peptide in the context of HLA-A2.27 Such bispecific antibodies with TCR specificity might be promising for targeting various tumour-specific intracellular proteins with oncogenic functions.